ClinicalTrials.gg
Active, not recruitingNCT03600233Updated Dec 23, 2025

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

A Phase 2 interventional study of CVM-1118 in Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor and Gastro-enteropancreatic Neuroendocrine Tumor, sponsored by TaiRx, Inc.. Active, not recruiting at 8 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by TaiRx, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Neuroendocrine Tumors with a site in Taiwan — 3 open to participants now, 5 under way, 1 of them phase 3. Neuroendocrine Tumors · Taiwan.

Started
2018
the only one that year
Phase 2
2 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
TaiRx, Inc.

Among the 10 studies in Neuroendocrine Tumors with a site in Taiwan, this one is the only one that started in 2018, is one of 2 in phase 2, and was the 8th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

3 of the 10 studies in Neuroendocrine Tumors with a site in Taiwan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Neuroendocrine Tumors with a site in Taiwan, or all of them as a file.
02

Study summary

CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.

Read the detailed description

Neuroendocrine tumors (NETs) are a group of uncommon heterogeneous malignancies originating from neuroendocrine cells localized throughout the body. Approximately 50% of patients with NETs would have metastatic cancer, where 65% of patients with metastatic cancer would result in mortality within 5 years of diagnosis.

The current treatments of NETs do not follow single discipline and the effective agents are largely still under clinical investigations. Apparent formation of vasculogenic mimicry (VM) has been reported in at least two types of NETs. Moreover, VM has been found as part of multiple microvascular alterations in mouse models of pancreatic neuroendocrine tumors.

Wih the high potential of inhibiting VM formation, CVM-1118 is considered to have therapeutic potentials in treating NET tumors.

03

Conditions studied

  • Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumor
  • Gastro-enteropancreatic Neuroendocrine Tumor
  • Lung Neuroendocrine Neoplasm
  • Neuroendocrine Carcinoma

Keywords

  • Oncology
  • Neuroendocrine Tumors
  • NET
  • Vasculogenic mimicry
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study must meet ALL of the following criteria:

  1. [Tumor eligibility] or cytologically confirmed advanced (unresectable and/or ) neuroendocrine tumors that are well-differentiated, low or intermediate grade (WHO Grade 1 or 2) of pancreatic or gastrointestinal, or low/ intermediate grade of lung origin, that are to standard of care therapy, or for whom no standard of care therapy is available.
  2. Patients must have measurable or evaluable disease as per criteria v1.1. Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy.
  3. Patients must have documented progressive disease within 6 months prior enrollment after prior therapy.
  4. Patients who are on therapy with a somatostatin analog are eligible but progressive disease must be demonstrated subsequent to establishment for at least 3 months of a stable dose.
  5. Male or female, 20 years of age or older.
  6. (ECOG) performance status 0 to 2.
  7. Resolution of all acute toxic effects of prior therapy or surgical procedures to Grade 1 (except alopecia).
  8. Adequate organ function as defined by the following criteria:

    • Serum (AST) and serum alanine transaminase (ALT) ≦ 3 x (ULN), or AST and ALT ≦ 5 x ULN if liver function abnormalities are due to underlying
    • Total serum ≦ 1.5 x ULN (except for patients with documented Gilbert's syndrome)
    • (ANC) ≧ 1500/µL
    • ≧ 90,000/µL
    • ≧ 9.0 g/dL
    • Serum creatinine ≦ 2.0 x ULN or of ≧ 50 mL/min
  9. Signed and dated document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
  10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

Patients eligible for this study must not meet ANY of the following criteria:

  1. Poorly differentiated neuroendocrine carcinoma, or high grade neuroendocrine tumor.
  2. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
  3. Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of starting study treatment.
  4. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.
  5. Current treatment on another clinical trial.
  6. Patients who are using other agents or who had received investigational drugs within 4 weeks prior to study enrollment.
  7. , spinal cord compression, carcinomatous meningitis, or unless appropriately treated and neurologically stable for at least 4 weeks.
  8. Any of the following within the 12 months prior to starting study treatment:

    myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including ; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the 6-month post-event-free period for a patient with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted.

  9. Hypertension that cannot be controlled by medications (> 160/100 mmHg despite optimal medical therapy).
  10. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
  11. Known history of (HIV) seropositivity and/or is receiving anti-retroviral therapy.
  12. virus (HBV) or virus (HCV) with evidence of chronic active disease or receiving/requiring antiviral therapy.
  13. History of receiving organ transplantation or immune disorders that require continuous agent therapy.
  14. Pregnancy or breastfeeding. Female patients must be surgically sterile or be or must agree to the use of effective during the period of therapy. All female patients with must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the Investigator or a designated associate.
  15. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or Sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    CVM-1118

    CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)

    Drug: CVM-1118

Interventions

  • Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose). Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.

    Also known as: TRX-818

06

What researchers measure

Primary outcomes

  1. Time-to progression-free survival (PFS)

    Measure the Time-to PFS or death to any cause. The tumor assessment will be performed every 12 weeks until documented disease progression, death, or date of follow-up.

    Time frame: 12 months after the last patient enrolled

Secondary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR), based on the investigator's assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1.

    Time frame: up to 12 months after the last patient enrolled

  2. Disease control rate (DCR)

    DCR is defined as the proportion of patients with a best overall response of CR, PR, or Stable Disease (SD), based on the investigator's assessment per RECIST criteria v1.1.

    Time frame: up to 12 months after the last patient enrolled

  3. Duration of overall response (DoR)

    DoR is measured only for the responder subset: patients with confirmed CR or PR based on the investigator's assessment. It is the elapsed time between the date of first documented response and the following date of event defined as the first documented disease progression or death due to underlying cancer, per RECIST criteria v1.1.

    Time frame: up to 12 months after the last patient enrolled

  4. Time-to progression (TTP)

    TTP is defined as the duration of time from initiation of study medication to first documentation of tumor progression.

    Time frame: up to 12 months after the last patient enrolled

  5. Time-to overall survival (OS)

    OS is defined as the duration of time from initiation of study medication to death due to any cause.

    Time frame: up to 12 months after the last patient enrolled

  6. Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v4.03

    Assessment of adverse events will based on the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\].

    Time frame: During the course of the trial or within 28 days following termination from the trial

  7. Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v4.03

    Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  8. Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v4.03

    Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  9. Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v4.03

    Normal range of PT/PTT will be provided. Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  10. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ body temperature by CTCAE v4.03

    Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  11. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure by CTCAE v4.03

    Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  12. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ heart rate by CTCAE v4.03

    Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  13. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v4.03

    Values with CTCAE v4.03 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  14. Abnormalities in electrocardiography (ECG)

    a 12-lead (with a 10-second rhythm strip) tracing, with a capacity to calculate the standard intervals automatically, will be used.

    Time frame: From baseline of screening up to end of treatment or withdraw, an average of 12 months

  15. Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing

    PK parameters will be calculated for CVM-1118 and its metabolite CVM-1125 during this study.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

  16. Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing

    PK parameters will be calculated for CVM-1118 and its metabolite CVM-1125 during this study.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

  17. Pharmacodynamics analysis for the relationship of Cmax and PFS

    The correlations of PK parameter, Cmax and key efficacy endpoint will be evaluated in this study.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

  18. Pharmacodynamics analysis for the relationship of AUC and PFS

    The correlations of PK parameter, AUC and key efficacy endpoint will be evaluated in this study.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

  19. Pharmacodynamics analysis for the relationship of AUC and AE

    The correlations of PK parameter, AUC and key safety endpoint will be evaluated in this study.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

  20. Pharmacodynamics analysis for the relationship of Cmax and AE

    The correlations of PK parameter, Cmax and key safety endpoint will be evaluated in this study.

    Time frame: Cycle 1 and Cycle 2 (each cycle is 28 days)

07

Study locations

8 sites
08

References and documents

Publications

  • Yen CJ, Chen MH, Chen YY, Bai LY, Chen JS, Hsieh JC, Shih YH, Wu IC, Chen YL, Chen CM, Chao TY, Chu YW, Chien DS. Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial. Br J Cancer. 2026 Jul 2. doi: 10.1038/s41416-026-03515-w. Online ahead of print. PubMed 42393461 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Sep 2024, 69 months.

Of 98 phase 2 interventional studies under Neuroendocrine Tumors, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 88. This study's 69 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2018
First posted
Jul 26, 2018
StartActual
Dec 15, 2018
Primary completionActual
Sep 30, 2024
CompletionEst.
Mar 31, 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03600233
Lead sponsor
TaiRx, Inc.
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Dec 15, 2018
Primary completion
Sep 30, 2024
Completion
Mar 31, 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Wu-Chou Su
principal investigator · National Cheng Kung University Hospital,Taiwan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Foslinanib

Start the discussion